MED.L Regulatory News (MED)

5 March 2018

MedaPhor Group plc

("MedaPhor" or the "Company")

Notice of Results

Investor results presentation

MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces it will be reporting its final results for the year ended 31 December 2017 on Wednesday, 21 March 2018.

Investor briefing

Stuart Gall (CEO), Wilson Jennings (FD) and Nicholas Sleep (CTO) will be hosting a briefing for investors on Wednesday, 21 March from 3.30pm to 5pm at the offices of IP Group. There will be an opportunity to see live demonstrations of a number of MedaPhor's products, including ScanTrainer, HeartWorks and the newly launched BodyWorks simulator platforms, as well as demonstrations of the new ScanNav technology currently under development.

To register to attend for the event and for further details, please contact Walbrook PR on 020 7933 8780 or medaphor@walbrookpr.com.

For further information, please contact:

About MedaPhor (investors.medaphor.com)

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.

 Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:

 Intelligent Ultrasound Simulation and Training

Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks Echocardiography simulator platform and BodyWorks Eve the Point of Care Ultrasound (PoCUS) simulator. Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.

Intelligent Ultrasound Clinical Support

Focuses on augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of obstetric scanning. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.

Some products in the pipeline may require US FDA approval, as such this material should be considered informational only and does not constitute an offer to sell, or infer, claims or benefits.